Headquartered in Bresso near Milan, Newron Pharmaceuticals focuses on discovering and developing therapies for diseases of the central and peripheral nervous systems. Its lead program is Evenamide, an oral molecule that selectively blocks sodium channels to modulate glutamate release, aiming to treat patients with schizophrenia who respond poorly or are resistant to current antipsychotics. The company’s most advanced effort is the global Phase III ENIGMA-TRS program, comprising the ENIGMA-TRS 1 and 2 studies. Proceeds from recent financing will be used to run these trials through to key read-outs expected by the end of 2026. Newron positions Evenamide as the first add-on therapy for treatment-resistant schizophrenia, addressing a significant unmet medical need. The latest capital raise also bolsters the firm’s balance sheet, supporting broader pipeline execution. No revenue or user metrics were disclosed in the article.

Total raised

$45M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2026